Schizophyllan inhibits the development of mammary and hepatic carcinomas induced by 7,12 dimethylbenz(α)anthracene and decreases cell proliferation: comparison with tamoxifen
- PMID: 22552717
- DOI: 10.1007/s00432-012-1224-0
Schizophyllan inhibits the development of mammary and hepatic carcinomas induced by 7,12 dimethylbenz(α)anthracene and decreases cell proliferation: comparison with tamoxifen
Abstract
Background: Breast cancer is one of the leading causes of cancer mortality among women. Some anticancer compounds have been isolated from mushrooms. The aim of the present work was to study the anticancer effects of schizophyllan (SCH), a β-D: -glucan extracted from the mushroom Schizophyllum commune alone or in combination with tamoxifen (TAM) on 7, 12 Dimethylbenz(α)anthracene (DMBA)-induced carcinomas in mice.
Methods: We isolated SCH from S. commune. Female mice received DMBA, SCH, DMBA+SCH, DMBA+TAM or DMBA+TAM+SCH or vehicles. We studied mice survival, tumour incidence, histopathology, oestrogen receptor (ER) expression, cell proliferation by immunohistochemical detection of proliferating cell nuclear antigen (PCNA), apoptosis by TUNEL assay, as well as caspase-3 expression.
Results: DMBA treatment resulted in mammary and hepatocellular carcinomas (HCC). Both SCH and TAM reduced the incidence of DMBA-induced mammary tumours by 85 and 75 %, respectively, and equally decreased the PCNA labelling index relative to DMBA. TAM treatment increased the incidence of- and PCNA index in HCCs relative to DMBA, while SCH suppressed these effects. TAM was more effective than SCH in the induction of apoptosis in both mammary and hepatic carcinomas. Caspase-3 levels correlated with the apoptotic index in most experimental groups.
Conclusions: Only one dose of SCH had similar therapeutic effects against DMBA-induced mammary carcinomas as 4 weeks of TAM treatment. This coupled with the ability of SCH to suppress hepatic lesions associated with TAM treatment provides the rationale for further investigating the combined therapeutic effects of TAM+SCH in preclinical models of ER-positive breast cancer, as well as in liver cancer.
Similar articles
-
Antitumor effects of droloxifene, a new antiestrogen drug, against 7,12-dimethylbenz(a)anthracene-induced mammary tumors in rats.Jpn J Pharmacol. 1991 Oct;57(2):215-24. doi: 10.1254/jjp.57.215. Jpn J Pharmacol. 1991. PMID: 1812300
-
Glycine soya diet synergistically enhances the suppressive effect of tamoxifen and inhibits tamoxifen-promoted hepatocarcinogenesis in 7,12-dimethylbenz[α]anthracene-induced rat mammary tumor model.Food Chem Toxicol. 2011 Feb;49(2):434-40. doi: 10.1016/j.fct.2010.11.020. Epub 2010 Nov 17. Food Chem Toxicol. 2011. PMID: 21092749
-
Effects of Jaeumkanghwa-tang on tamoxifen responsiveness in preclinical ER+ breast cancer model.Endocr Relat Cancer. 2019 Mar 1;26(3):339-353. doi: 10.1530/ERC-18-0393. Endocr Relat Cancer. 2019. PMID: 30640711 Free PMC article.
-
Effects of tamoxifen and melatonin on mammary gland cancer induced by N-methyl-N-nitrosourea and by 7,12-dimethylbenz(a)anthracene, respectively, in female Sprague-Dawley rats.Folia Biol (Praha). 2001;47(1):5-10. Folia Biol (Praha). 2001. PMID: 11232869
-
Effects of In Utero Exposure to Ethinyl Estradiol on Tamoxifen Resistance and Breast Cancer Recurrence in a Preclinical Model.J Natl Cancer Inst. 2016 Sep 8;109(1):djw188. doi: 10.1093/jnci/djw188. Print 2017 Jan. J Natl Cancer Inst. 2016. PMID: 27609189 Free PMC article.
Cited by
-
Molecular interaction and MD-simulations: investigation of Sizofiran as a promising anti-cancer agent targeting eIF4E in colorectal cancer.In Silico Pharmacol. 2024 Apr 21;12(1):33. doi: 10.1007/s40203-024-00206-3. eCollection 2024. In Silico Pharmacol. 2024. PMID: 38655099
-
Mycobiota and C-Type Lectin Receptors in Cancers: Know thy Neighbors.Front Microbiol. 2022 Jul 13;13:946995. doi: 10.3389/fmicb.2022.946995. eCollection 2022. Front Microbiol. 2022. PMID: 35910636 Free PMC article. Review.
-
Interactions Between Natural Products and Tamoxifen in Breast Cancer: A Comprehensive Literature Review.Front Pharmacol. 2022 Jun 2;13:847113. doi: 10.3389/fphar.2022.847113. eCollection 2022. Front Pharmacol. 2022. PMID: 35721162 Free PMC article. Review.
-
Anticancer Activities of Mushrooms: A Neglected Source for Drug Discovery.Pharmaceuticals (Basel). 2022 Jan 31;15(2):176. doi: 10.3390/ph15020176. Pharmaceuticals (Basel). 2022. PMID: 35215289 Free PMC article. Review.
-
Mycobiome and Cancer: What Is the Evidence?Cancers (Basel). 2021 Jun 24;13(13):3149. doi: 10.3390/cancers13133149. Cancers (Basel). 2021. PMID: 34202433 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous